“With selective access to aggregate data, stakeholders might mitigate potential drug shortages. Sensitive gene therapies and personalized medicine could be more easily tracked on their way to individual patients. Ultimately we’re looking at a supply chain that is faster, more efficient, more flexible, and better equipped to handle shocks like …

“From a dispenser’s perspective, the DSCSA checks will be expensive and we want to get value from this process. Even more, we don’t want drugs to pile up while we are waiting on verification, so the verification should be nearly real-time.”